Trial Profile

A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Sep 2024 Results assessing the exposure-response relationships in induction and maintenance study considering patients baseline characteristics from SERENE ER Analysis Part 1-SERENE CD trial, published in the Clinical Pharmacology in Drug Development.
11 Mar 2023 Results assessing the impact of immunogenicity and improving prediction of trough concentrations of Adalimumab in patients with Crohns Disease and Ulcerative Colitis from SERENE CD (NCT02065570) and SERENE UC (NCT02065622) studies, published in the Clinical Pharmacokinetics.
02 Feb 2022 Results published in the Gastroenterology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com